Chitosan oligosaccharide improves the therapeutic efficacy of sitagliptin for the therapy of Chinese elderly patients with type 2 diabetes mellitus

Sitagliptin improves glycemic control in type 2 diabetes mellitus (T2DM) patients but its side effects are undesirable. Chitosan oligosaccharide (COS) is expected to improve the therapeutic result as a natural product. A total of 200 elderly T2DM patients were evenly assigned into four groups: sitag...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Lijie, Sun, Tingli, Wang, Lina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499789/
https://www.ncbi.nlm.nih.gov/pubmed/28721055
http://dx.doi.org/10.2147/TCRM.S134039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499789/
https://www.ncbi.nlm.nih.gov/pubmed/28721055
http://dx.doi.org/10.2147/TCRM.S134039

Ejemplares similares